USC Study Identifies Three Unique Cognitive Decline Tracks in Asymptomatic Alzheimer’s Patients

Researchers identify three distinct tracks for Alzheimer’s progression using P-tau217 markers, potentially revolutionizing early diagnosis and clinical trials.

By: AXL Media

Published: Apr 28, 2026, 9:24 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Departure From Uniform Diagnostic Assumptions

The prevailing medical understanding that Alzheimer’s disease follows a predictable, linear path toward cognitive impairment has been challenged by new data from the Keck School of Medicine. In a study involving participants who initially showed no external symptoms, researchers identified three distinct patterns of progression, classified as stable, slow decline, and fast decline. According to Michael Donohue, a professor of neurology at USC, treating all patients as if they worsen at a uniform rate masks critical individual differences. This finding suggests that the preclinical phase of the disease is far more variable than previously documented in standard medical literature.

Biomarker Indicators and Predictive Modeling

The research successfully linked specific biological indicators to the speed at which a person’s cognitive abilities may diminish. By examining blood tests and neuroimaging, scientists identified that elevated levels of P-tau217, a specific protein marker, served as a primary signal for future impairment. Additionally, those who fell into the fast decline category often exhibited higher tau levels on brain scans and a noticeably smaller hippocampus at the start of the observation period. This focus on biological data allowed the team to categorize the progression of participants with a significant degree of accuracy, providing a potential roadmap for earlier, more personalized medical intervention.

Data Sourced From Collaborative Clinical Trials

To establish these findings, the research team analyzed longitudinal data from two major sources, the A4 study and the LEARN study. These projects tracked memory, attention, and general thinking skills over a period of approximately six years, providing a robust dataset for statistical modeling. While the majority of participants, roughly 70%, remained cognitively stable throughout the duration of the study, the remaining group showed measurable drops in test scores. These variations highlight the necessity of looking beyond the average experiences of trial participants to understand the nuanced reality of those living with early-stage amyloid risks.